Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- Chimeric receptor T-cells + Trastuzumab
- Conditions
- HER2+ Advanced Breast Cancer
- Sponsor
- National University Hospital, Singapore
- Enrollment
- 36
- Primary Endpoint
- Duration of tumour response
- Status
- Not yet recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
This phase Ib study aims to assess the safety and feasibility of combination of chimeric receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion of study population in HER2+ metastatic breast cancer once safety has been established.
Detailed Description
Hypothesis Investigators hypothesize that trastuzumab-mediated cytotoxicity will be augmented by the infusion of autologous chimeric receptor T-cells. Primary Objectives 1. To determine the safety of autologous chimeric receptor T-cells in patients with HER2+ advanced solid tumors 2. To determine the clinical benefit rate (CBR) of autologous chimeric receptor T-cells in patients with HER2+ advanced breast cancer Secondary Objectives 1. To determine the expansion and persistence of autologous chimeric receptor T-cells after a single infusion in patients with advanced solid tumors 2. To determine anti-tumor efficacy in terms of objective response rate (ORR) and progression-free survival (PFS) of autologous chimeric receptor T-cells in patients with HER2+ advanced breast cancer
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients may be included in the study only if they meet all of the following criteria:
- •Age ≥ 21 years.
- •Histologically confirmed diagnosis of HER2-positive cancer defined by immunohistochemistry (IHC) to be HER2 IHC3+ or HER2 IHC2+ and FISH positive. If immunohistochemistry is not available, FISH method is acceptable. The HER2 positivities by FISH is determined as FISH amplification ratio positive by institutional guidelines. Tumor subtype for each phase include :
- •Phase I: HER2-positive breast or gastric cancer or other treatment-refractory HER2-positive solid tumors
- •Phase II : HER2-positive breast carcinoma
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Has measurable or evaluable disease based on RECIST 1.1 criteria
- •Estimated life expectancy of at least 12 weeks.
- •Prior lines of therapy:
- •HER2-positive breast cancer - patient must have failed at least two lines of anti-HER2 based therapy for advanced/metastatic cancer. Patients with documented relapse while receiving or within 6 months of completion of adjuvant or neoadjuvant trastuzumab for HER2-positive breast cancer will be considered as 1 prior line of therapy.
Exclusion Criteria
- •Patients will be excluded from the study for any of the following reasons:
- •Treatment within the last 30 days with any investigational drug.
- •Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.
- •Major surgery within 28 days of study drug administration.
- •Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
- •Pregnancy.
- •Breast feeding.
- •Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
- •Active bleeding disorder or bleeding site.
- •Non-healing wound.
Arms & Interventions
Chimeric Receptor T-cells
Eligible patients will undergo apheresis prior to cycle 1 therapy. Treatment comprises of trastuzumab followed by chimeric receptor T-cells in cycle 1. During Cycle 2 onwards till disease progression, patients will receive IV or SC trastuzumab only, every 3 weeks.
Intervention: Chimeric receptor T-cells + Trastuzumab
Chimeric Receptor T-cells
Eligible patients will undergo apheresis prior to cycle 1 therapy. Treatment comprises of trastuzumab followed by chimeric receptor T-cells in cycle 1. During Cycle 2 onwards till disease progression, patients will receive IV or SC trastuzumab only, every 3 weeks.
Intervention: Fludarabine and Cyclophosphosphamide
Outcomes
Primary Outcomes
Duration of tumour response
Time Frame: 3 Years
Among tumor responders, the duration of tumor response is measured from the date of enrolment until the first date of documented disease progression or death due to any cause, whichever occurs first. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.
Time to treatment failure
Time Frame: 3 years
defined as the time from the date of study enrolment to the date of the first of the following events: early discontinuation of study therapy, progressive disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for patients who did not discontinue early, who are still alive, and who have not progressed.
Progression-free survival
Time Frame: 3 Years
is defined as the time from the date of study enrolment to the first date of documented disease progression. Progression-free survival will be censored at the date of death for patients who have not had documented disease progression. For patients who are still alive at the time of analysis and who have not had documented disease progression, progression-free survival will be censored at the date of the last follow-up visit.